News
December
13
2018
Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
October
18
2018
What Makes RT001 Unique?
Retrotope released new data at the National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) regarding the impact of RT001 on disease progression in 2 patients with infantile neuroaxonal dystrophy (INAD). Dr. Mark Midei discusses what makes RT001 unique.
Read more
October
14
2018
Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
October
04
2018
Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients.
July
09
2018
Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology, and Interim Chair of the Department of Neurology at UCLA, have published a paper demonstrating that the Company’s D-PUFA drug candidate, RT001, reduces cognition deficits in a preclinical in vivo model of Huntington’s disease, while simultaneously downregulating brain lipid peroxidation biomarkers. The paper, entitled “Deuterium‐ reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease,” was published in The FEBS Journal.
Read more
July
09
2018
Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
June
28
2018
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
April
24
2018
Retrotope Announces RT001 Clinical Data Presentation at the 2018 American Academy of Neurology (AAN) Annual Meeting.
April
18
2018
Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia
November
16
2017
Retrotope initiates second patient for Compassionate Use of RT001 for an ultra-rare genetic neurological disease, Infantile Neuroaxonal Dystrophy
November
02
2017
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration.
October
27
2017
Study of Retrotope’s patented deuterated polyunsaturated fatty acid drugs is published in The FEBS Journal, and shows drugs fully rescue Alzheimer’s loss of cognition in a mouse model.
April
26
2017
Retrotope and collaborators to present poster at the 2017 American Academy of Neurosciences Meeting in Boston on stabilized PUFA drug efficacy in multiple Alzheimer’s models.
April
02
2017
Making a Better You (Dr. Harry J. Saal) TEDxPaloAlto 4-2-2017
In this 18 minute presentation, Dr. Harry J. Saal, Retrotope’s Chairman, explains to a TEDx audience how Retrotope’s technology impacts the membranes that are frequently damaged in many neurological diseases.
Read more
April
02
2017
Retrotope to present first human data on the safety and early efficacy of its novel stabilized lipid drug platform against neurodegeneration.
January
25
2017
Isotope Effect: A New Approach to Combating Neurological and Mitochondrial Diseases.
A presentation at the Moscow State University by CSO Dr. Misha Shchepinov regarding the mechanism of action of Retrotope's RT001, and its effectiveness in a variety of disease models.
Read more
September
15
2016
Retrotope announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s ataxia.
June
01
2016
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the treatment of Friedreich’s ataxia. First-in-human clinical trial for RT001 is now fully enrolled.
February
19
2016
Retrotope advances RT001 in clinical trials to treat Friedreich’s ataxia. Announces open enrollment of highest dose cohort after safety review